NuView Life Sciences announced entry into an exclusive global licensing and collaboration agreement with Otsuka Pharmaceutical to further develop and commercialize NuView's investigative genomic-based diagnostic biomarker to detect cancers of the breast and prostate.
The agreement also includes all other future diagnostic-imaging applications.
NuView retains all rights for the VPAC1 compound for in-vivo therapeutic delivery and in-vitro urine screen applications.
Otsuka will provide funding for all future clinical trials and commercialization of the VPAC1 biomarker worldwide.
Otsuka intends to utilize NuView's manufacturing subsidiary, US Radiopharmaceuticals to meet requirements for clinical trials through future commercialization upon approval. The two companies anticipate initiating a Phase I trial in the U.S. in the coming months. The VPAC1 biomarker originated at Thomas Jefferson University (TJU) Philadelphia, PA.
View: M&A Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity